Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor

For patients with inoperable neuroendocrine tumors (NETs) expressing somatostatin receptors, peptide receptor radionuclide therapy (PRRT) with (177)Lu-[DOTA0-Tyr3]-octreotate ((177)Lu-octreotate) is one of the most promising targeted therapeutic options but it rarely achieves cure. Therefore, differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Purohit, Nupur K., Shah, Rashmi G., Adant, Samuel, Hoepfner, Michael, Shah, Girish M., Beauregard, Jean-Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973847/
https://www.ncbi.nlm.nih.gov/pubmed/29872498
http://dx.doi.org/10.18632/oncotarget.25266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973847/
https://www.ncbi.nlm.nih.gov/pubmed/29872498
http://dx.doi.org/10.18632/oncotarget.25266

Ejemplares similares